NuCana Goodwill and Intangible Assets 2017-2025 | NCNA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

NuCana goodwill and intangible assets from 2017 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

NuCana goodwill and intangible assets from 2017 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$237.5B
Amgen (AMGN)	$162B
Gilead Sciences (GILD)	$142.8B
Vertex Pharmaceuticals (VRTX)	$120.5B
Bristol Myers Squibb (BMY)	$93.6B
CSL (CSLLY)	$84.5B
GSK (GSK)	$79.6B
Regeneron Pharmaceuticals (REGN)	$59.9B
Alnylam Pharmaceuticals (ALNY)	$44.3B
Argenex SE (ARGX)	$36.7B
BioNTech SE (BNTX)	$26.5B
Royalty Pharma (RPRX)	$20.9B
Insmed (INSM)	$20B
Biogen (BIIB)	$18.6B
Illumina (ILMN)	$16.9B
Incyte (INCY)	$15B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14.3B
Moderna (MRNA)	$12.4B
BioMarin Pharmaceutical (BMRN)	$11.3B
QIAGEN (QGEN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.2B
Exelixis (EXEL)	$9.9B
Bio-Techne Corp (TECH)	$9B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.8B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.7B
Legend Biotech (LEGN)	$7.4B